[1]冯蓬,朱立国,孙凯,等.壮腰通络方治疗盘源性腰痛的临床研究[J].中国中医骨伤科杂志,2023,31(06):61-65+70.[doi:10.20085/j.cnki.issn1005-0205.230611]
　FENG Peng,ZHU Liguo,SUN Kai,et al.Clinical Study on Zhuangyao Tongluo Decoction on the Treatment of Discogenic Low Back Pain[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2023,31(06):61-65+70.[doi:10.20085/j.cnki.issn1005-0205.230611]
点击复制

壮腰通络方治疗盘源性腰痛的临床研究()
分享到：

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第31卷
期数:
2023年06期
页码:
61-65+70
栏目:
临床报道
出版日期:
2023-06-15

文章信息/Info

Title:
Clinical Study on Zhuangyao Tongluo Decoction on the Treatment of Discogenic Low Back Pain
文章编号:
1005-0205(2023)06-0061-05
作者:
冯蓬1; 朱立国1; 2; 孙凯1; 李路广1; 高景华1; 李建国1; 高春雨1△
1中国中医科学院望京医院(北京,100020)
2中医正骨技术北京市重点实验室
Author(s):
FENG Peng1; ZHU Liguo1; 2; SUN Kai1; LI Luguang1; GAO Jinghua1; LI Jianguo1; GAO Chunyu1△
1Wangjing Hospital of China Academy of Chinese Medical Sciences,Beijing 100020,China;
2Beijing Key Laboratory of Orthopedics of Traditional Chinese Medicine,Beijing 100007,China.
关键词:
盘源性腰痛;  壮腰通络方;  临床疗效;  安全性评价
Keywords:
discogenic low back pain;  Zhuangyao Tongluo decoction;  clinical efficacy;  adverse effect assessment
分类号:
R274.9
DOI:
10.20085/j.cnki.issn1005-0205.230611
文献标志码:
B
摘要:
目的:研究壮腰通络方治疗盘源性腰痛(肝肾亏虚、瘀血阻络证)的临床疗效,并评估药物安全性。方法:选取盘源性腰痛(肝肾亏虚、瘀血阻络证)患者42例,利用随机数字表法将患者随机分为治疗组(23例)和对照组(19例)。治疗组给予壮腰通络方治疗,对照组给予塞来昔布胶囊治疗。比较两组不同治疗时期患者的组内和组间的腰痛视觉模拟量表(VAS)评分、Oswestry功能障碍指数(ODI)、谷丙转氨酶(ALT)、谷草转氨酶(AST)表达水平以及治疗前后的腰椎MRI影像。结果:两组患者腰部疼痛VAS评分比较,两组患者分组因素和时间因素存在交互效应,差异有统计学意义(P<0.05); 两组患者总体疼痛VAS评分比较无分组效应,差异无统计学意义(P>0.05),但不同时间点对比存在时间效应(P<0.05); 在治疗1周后,治疗组VAS评分高于对照组,差异有统计学意义(P<0.05); 在治疗1个月后,治疗组低VAS评分于对照组,差异有统计学意义(P<0.05); 两组患者不同时间点VAS评分呈现下降趋势。两组患者腰部功能ODI评分比较,两组患者时间因素和分组因素均存在交互效应,差异有统计学意义(P<0.05); 两组患者总体ODI评分比较存在分组效应,差异有统计学意义(P<0.05),不同时间点比较存在时间效应,差异有统计学意义(P<0.05); 在治疗1周后,治疗组ODI评分高于对照组,差异有统计学意义(P<0.05); 在治疗1个月后,治疗组ODI评分低于对照组,差异有统计学意义(P<0.05); 两组不同时间点ODI评分均呈现下降趋势。两组患者治疗前后的MRI Pfirrmann分级没有明显改变,差异无统计学意义(P>0.05)。两组患者治疗期间均未发现明显的药物不良反应,且治疗前后谷丙转氨酶和谷草转氨酶水平没有显著变化,差异无统计学意义(P>0.05)。结论:壮腰通络方治疗盘源性腰痛(肝肾亏虚、瘀血阻络证),可以缓解患者的腰痛症状,改善患者的腰椎功能,具有明确的临床疗效且临床应用安全性较好。
Abstract:
Objective:To investigate the clinical efficacy of Zhuangyao Tongluo decoction for the treatment of discogenic low back pain(liver-kidney deficiency,blood stasis syndrome)and to evaluate the herbal medicine safety.Methods:42 patients with discogenic low back pain(liver-kidney deficiency,blood stasis syndrome)were selected,and the patients were randomly divided into treatment group(23 cases)and control group(19 cases)using the random number table method.The treatment group was given Zhuangyao Tongluo decoction treatment,and the control group was given celecoxib capsule.Visual analogue scale(VAS)for low back pain,Oswestry disability index(ODI),alanine transaminase(ALT),and aspartate transaminase(AST)expression levels,and MRI of the lumbar spine before and after treatment were compared within and between the two groups.Results:Compared with the VAS between the two groups,there was an interaction effect between the grouping factor and the time factor in the two groups(P<0.05).There was no grouping effect in the overall VAS of the two groups(P>0.05),but there was a time effect at different time points(P<0.05).At 1 week of treatment,the treatment group was higher than the control group,and the difference was statistically significant(P<0.05).After 1 month of treatment,the treatment group was lower than the control group,and the difference was statistically significant(P<0.05); the VAS scores of the two groups showed a downward trend at different time points.Comparing the ODI scores of lumbar function between the two groups,there was an interaction effect between the time factor and the grouping factor in the two groups(P<0.05).There was a grouping effect in the comparison of the overall ODI scores of the two groups(P<0.05),and a time effect at different time points(P<0.05).At 1 week of treatment,the treatment group was higher than the control group,and the difference was statistically significant(P<0.05).After 1 month of treatment,the treatment group was lower than the control group,and the difference was statistically significant(P<0.05).The ODI scores of the two groups showed a downward trend at different time points.The MRI Pfirrmann grades of the two groups before and after treatment did not change significantly,and the difference was not statistically significant(P>0.05).No obvious adverse drug reactions were found in the two groups during treatment,and the levels of ALT and AST had no significant changes before and after treatment,and the difference was not statistically significant(P>0.05).Conclusion:The treatment of discogenic low back pain(liver-kidney deficiency,blood stasis syndrome)by Zhuangyao Tongluo decoction can effectively relieve the symptoms of low back pain and effectively improve the lumbar function of patients,with good safety for clinical application.

参考文献/References:

[1] KNEZEVIC N N,CANDIDO K D,VLAEYEN J S,et al.Low back pain[J].Lancet,2021,398(10294):78-92.
[2] SIMON J,MCAULIFFE M,SHAMIM F,et al.Discogenic low back pain[J].Phys Med Rehabil Clin N Am,2014,25(2):305-317.
[3] ZHANG Y G,GUO T M,GUO X,et al.Clinical diagnosis for discogenic low back pain[J].Int J Biol Sci,2009,5(7):647-658.
[4] ZHAO L,MANCHIKANTI L,KAYE A D,et al.Treatment of discogenic low back pain:current treatment strategies and future options-a literature review[J].Curr Pain Headache Rep,2019,23(11):86.
[5] FUJII K,YAMAZAKI M,KANG J D,et al.Discogenic back pain:literature review of definition,diagnosis,and treatment[J].J BMR Plus,2019,3(5):e10180.
[6] 朱立国,孙凯,魏戌,等.《外台秘要》腰痛方证治特点及用药规律探析[J].世界中西医结合杂志,2019,14(9):1188-1190.
[7] 孙凯,朱立国,魏戌,等.壮腰通络方治疗腰椎间盘突出症45例[J].中国中医骨伤科杂志,2021,29(1):19-23.
[8] FISCHGRUND J S,MONTGOMERY D M.Diagnosis and treatment of discogenic low back pain[J].Orthop Rev,1993,22(3):311-318.
[9] FAIRBANK J C,PYNSENT P B.The Oswestry disability index[J].Spine(Phila Pa 1976),2000,25(22):2940-2952.
[10] PFIRRMANN C W,METZDORF A,ZANETTI M,et al.Magnetic resonance classification of lumbar intervertebral disc degeneration[J].Spine(Phila Pa 1976),2001,26(17):1873-1878.
[11] REDDY R.A review of discogenic pain management by interventional techniques[J].J Craniovertebr Junction Spine,2020,11(1):4-8.
[12] 孙凯,朱立国,魏戌,等.基于UPLC-Q-TOF-MS/MS结合网络药理学的壮腰通络方延缓腰椎间盘退行性病变的化学成分及作用机制研究[J].中国全科医学,2021,24(35):4437-4446.
[13] 庄明辉,于杰,冯敏山,等.浅析朱立国治疗脊柱退行性疾病常用中药药对[J].中华中医药杂志,2020,35(1):219-221.
[14] 王尚全,孙树椿,陈明,等.清宫正骨流派学术思想初探[J].中国中医骨伤科杂志,2017,25(9):68-70.
[15] 孙凯,魏戌,朱立国,等.壮腰通络方对腰椎间盘退行性病变大鼠病理变化及血清炎症因子表达的影响[J].中国中医药信息杂志,2022,29(7):93-98.
[16] GRIFFITH J F,XIANG Y,WANG J,et al.Modified Pfirrmann grading system for lumbar intervertebral disc degeneration[J].Spine(Phila Pa 1976),2007,32(24):E708-E712.

备注/Memo

备注/Memo:
基金项目:国家中医药管理局中医药创新团队及人才支持计划项目(ZYYCXTD-C-202003)
△通信作者 E-mail:gaochunyu8526@sina.com
更新日期/Last Update: 2023-06-10